MAYFAIR, U.K. - TelAve -- Brookstreet Equity Partners LLP, a London-based, award-winning investment manager, today confirmed that Dr Oliver Zolman  has joined the firm as Executive in Residence (EIR), further strengthening its capabilities in longevity science and next-generation healthcare.

(PR Extract)

Dr Zolman trained in regenerative and evidence-based medicine and has developed comprehensive frameworks to assess whole-body ageing. His work focuses on expanding the boundaries of what can be measured, tracked, and optimised in human biology through structured, data-driven approaches.

He is the architect of the "82 Organs Framework", a system designed to assess and optimise function across the body at an organ-system level, and is connected to a global network of over 500 longevity-focused clinicians.

More on TelAve News

• GitKraken Desktop 12.0 Introduces Agent Mode: Gives Developers Ultimate Control & Visualization While Scaling Parallel Agent Workflows
• 5 Things to Check Before Calling for AC Repair in Philly
• Go Dental Clinic Announces Upcoming Opening of New Branch in International City, Dubai
• Hazel E Hosts Starline Tours Bus to Sonic Desert - A Launch to Coachella
• Contracting Resources Group and Aalis Management Consulting Launch ARG Joint Venture Under SBA Mentor-Protégé Program

Dr Zolman has contributed to frontier initiatives in the field, including being recruited for involvement in the $101 million "XPRIZE Healthspan Prize", and created "Project Blueprint" for Bryan Johnson (one of the most visible personalised longevity programmes globally) using his Longevity "Level 1-2-3" protocol, built on the principle that ageing can be quantified, monitored, and systematically improved through disciplined, multi-variable intervention.

His work and perspectives have been featured across major international media, including Netflix, BBC, Bloomberg, and The Times, reflecting the growing relevance of longevity science in mainstream healthcare and global discourse.

In his role as Executive in Residence, Dr Zolman will work closely with Brookstreet's investment team to support the evaluation of longevity-focused opportunities, contribute domain expertise to due diligence and portfolio development, and help shape new strategies within this rapidly evolving sector.

Brookstreet is focused on high-velocity capital deployment across sectors including AI-enabled enterprise, energy transition, longevity, and dual-use technologies.

More on TelAve News

• Card makers turn to Pink and Main for tools to support their craft
• Revenue Optics Completes Full Commercial Buildout. A Nine-Month-Old Firm Built on 25 Years of Distribution Expertise. Five Clients From $200M to $3B
• EduCare Inc. Bridges Critical Gap in Breast Cancer Education with Spanish COPE Library Launch
• Engineering leaders from industry, academia to gather at IISE Annual Conference & Expo in Arlington, Texas
• AI-Driven Neurotechnology Expansion as FDA Path Clears and New Defense Initiative Emerges for NRx Pharmaceuticals (N A S D A Q: NRXP)

Omiros D. Sarikas, Managing Partners of Brookstreet, commented:

"Longevity is emerging as one of the most important investment frontiers of the next decade, combining advances in biology, data, AI, and clinical innovation. Dr Zolman operates at the intersection of these domains. His systems-based perspective and translational expertise are closely aligned with our approach to clinical longevity, prioritising scientific evidence over transient market dynamics.

Dr Zolman added:

"Ageing is no longer something we simply observe; it is increasingly something we can measure, model, and influence. The opportunity now lies in translating this understanding into structured, scalable systems. I am pleased to collaborate with Brookstreet, where frontier, clinically grounded science can be translated into real-world applications to extend healthspan, and, ultimately, lifespan.

Learn more: https://www.brookstreetequity.com/news/dr-oliver-zolman-collaborates-with-brookstreet